Immune Regulation appoints new CEO

Jonathan Rigby has been appointed CEO of Immune Regulation, a London-based clinical stage biotech focussed on for inflammatory and immunological diseases.

Based in the US, Mr Rigby, who also joins the Board of Directors, brings decades of pharma, biotech and drug delivery technology experience.

In 2011, he became the CEO of SteadyMed Therapeutics and focused the company on the development of drug device combination products to treat Pulmonary Hypertension.

He led the company through a Nasdaq listing in 2015 and a public-to-public company sale to United Therapeutics in late 2018.

In 2006 he cofounded Zogenix, a specialty pharmaceutical company now focused on the development and commercialisation of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010.

Earlier in his career, he held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics (now Phillips Medical).

He replaces outgoing Chief Executive Richard Nagle, who has led the business since 2017.

Immune Regulation Chairman, Dr Dominik Escher, said that Mr Rigby is “the ideal candidate to lead the next stage of clinical development of our two key therapies in immune system resetting”.

Mr Rigby said: “The Company has first-in-class immune-resetting therapies with a broad potential to treat autoimmune diseases. For example, IRL201805 and IRL201104 have shown considerable efficacy in preclinical and human clinical studies in rheumatoid arthritis and asthma / severe allergy respectively.

“We are also in the early stages of assessing the potential of IRL1104 to reduce lung inflammation which may be a consequence in patients infected by the COVID-19 virus.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...